Fig. 1From: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancerDuration of exposure to pembrolizumab and summary of best overall response (N = 22) aPatient was considered clinically stable per investigator’s judgment and was permitted to continue treatment after progressive diseaseBack to article page